Rathbone Brothers plc Decreases Position in GW Pharmaceuticals PLC- (GWPH)

Rathbone Brothers plc trimmed its holdings in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 23.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 18,540 shares of the biopharmaceutical company’s stock after selling 5,706 shares during the quarter. Rathbone Brothers plc’s holdings in GW Pharmaceuticals PLC- were worth $3,203,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GWPH. Wells Fargo & Company MN increased its stake in shares of GW Pharmaceuticals PLC- by 20.6% in the 1st quarter. Wells Fargo & Company MN now owns 29,172 shares of the biopharmaceutical company’s stock worth $3,288,000 after acquiring an additional 4,987 shares in the last quarter. JPMorgan Chase & Co. increased its stake in GW Pharmaceuticals PLC- by 4,345.8% during the 1st quarter. JPMorgan Chase & Co. now owns 20,984 shares of the biopharmaceutical company’s stock valued at $2,364,000 after purchasing an additional 20,512 shares in the last quarter. Sei Investments Co. increased its stake in GW Pharmaceuticals PLC- by 3,653.6% during the 1st quarter. Sei Investments Co. now owns 2,102 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 2,046 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in GW Pharmaceuticals PLC- by 48.2% during the 1st quarter. Commonwealth Equity Services LLC now owns 10,383 shares of the biopharmaceutical company’s stock valued at $1,169,000 after purchasing an additional 3,376 shares in the last quarter. Finally, UBS Group AG increased its stake in GW Pharmaceuticals PLC- by 74.2% during the 1st quarter. UBS Group AG now owns 82,911 shares of the biopharmaceutical company’s stock valued at $9,341,000 after purchasing an additional 35,318 shares in the last quarter. Institutional investors own 75.44% of the company’s stock.

A number of analysts have weighed in on the stock. ValuEngine lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Cantor Fitzgerald set a $235.00 price objective on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research note on Thursday, July 12th. Stifel Nicolaus assumed coverage on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, August 14th. They set a “buy” rating and a $181.00 price objective for the company. BidaskClub upgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Saturday, August 11th. Finally, Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $185.00.

NASDAQ:GWPH opened at $143.32 on Friday. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of -20.62 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. GW Pharmaceuticals PLC- has a fifty-two week low of $101.07 and a fifty-two week high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The business had revenue of $3.46 million during the quarter, compared to analyst estimates of $2.00 million. Equities research analysts expect that GW Pharmaceuticals PLC- will post -9.11 earnings per share for the current year.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply